The HIV protease inhibitor Tipranavir is marketed for the treatment of AIDS. The first enantioselective medicinal chemistry route to Tipranavir included the conjugate addition of an organocuprate reagent to a chiral Michael acceptor. The chiral oxazolidinone in the Michael acceptor controlled the stereochemistry of one of two stereocenters in the molecule. The final, commercial route to Tipranavir does not feature a chiral auxiliary; instead, this stereocenter is set by an asymmetric hydrogenation reaction.